Amgen’s feedback Thursday that it’s “very inspired” by interim Section 2 information for its weight problems drug have rapidly sparked immense investor curiosity in what could possibly be a possible contender with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
The injectable drug MariTide, designed to be given month-to-month, could possibly be a extra enticing possibility than Wegovy and Zepbound, that are each dosed weekly. Whereas the Section 2 trial remains to be ongoing, Amgen is already planning to run a broad Section 3 program and scale up manufacturing “with each scientific and industrial provide in thoughts,” Chief Govt Bob Bradway mentioned on an earnings name.
Although executives shared no information from the interim evaluation of its injectable drug, pleasure across the molecule has already despatched Amgen’s refill 12% Friday.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
View All Plans
